secwatch.observer — SEC 8-K summary
======================================

Issuer:     Stoke Therapeutics, Inc. (STOK)
CIK:        0001623526
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001193125-26-212020
Event type: earnings
Sentiment:  neutral
Materiality: 0.78
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Stoke reports Q1 net loss $50M; new 4-year OLE data supports zorevunersen disease-modifying potential
--------------------------------------------------------------------------------

- Net loss $50.0M ($0.79/share) vs prior-year net income $112.9M; revenue $6.2M down from $158.6M due to 2025 Biogen license revenue.
- Cash $411M funded into 2028; includes $80.7M from ATM sales of 2.6M shares in Q1.
- New 4-year OLE data: durable seizure reductions, statistically significant cognition/behavior gains at 1-4 years; generally well tolerated.
- Phase 3 EMPEROR enrollment (~150 pts) expected to complete June 2026, data readout mid-2027; NDA submission planned Q1 2027.
- First patient dosed in Phase 1 OSPREY (STK-002 for ADOA); SYNGAP1 candidate selection targeted in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1623526/000119312526212020/0001193125-26-212020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1623526/000119312526212020/stok-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-212020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer